Clinical Trials Directory

Trials / Unknown

UnknownNCT02683733

Bio-enhanced Curcumin as an Add-On Treatment in Mild to Moderate Ulcerative Colitis

The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Asian Institute of Gastroenterology, India · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Inflammatory Bowel Disease, including ulcerative colitis, is thought to result from an imbalance of pro-inflammatory and anti-inflammatory factors. As such, the majority of treatment options are directed at attempting to control the chronic inflammation and prolonging remission of clinical symptoms. Several studies have proven that curcumin has well-established anti-inflammatory properties. However, curcumin has poor bioavailability and prior studies have needed to use high concentrations in order to study the efficacy of the product. The investigators propose that a bio-enhanced preparation of curcumin will require a lower dosage to reach and affect its target tissue and will subsequently produce less adverse side effects.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTBio-enhanced Curcumin Soft Gelatin CapsuleEach capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
DRUG5-Aminosalicylic acidDosage is as instructed by patient's physician

Timeline

Start date
2016-02-01
Primary completion
2017-02-01
First posted
2016-02-17
Last updated
2016-02-23

Locations

1 site across 1 country: India

Source: ClinicalTrials.gov record NCT02683733. Inclusion in this directory is not an endorsement.